Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous Bicarbonate To Verify The Correct Position of IV Catheters in Oncological Patients Oncological Patients Receiving Chemotherapy (IVBICONCOL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Sheba Medical Center
Netherlands: Ministry of Health, Welfare and Sports
Information provided by (Responsible Party):
Dr. Ilan Keidan, Sheba Medical Center Identifier:
First received: December 10, 2012
Last updated: December 30, 2012
Last verified: December 2012

The investigators use bicarbonate injected to an intravenous line and the changes in the exhaled end-tidal carbon dioxide to verify whether the IV line is in the vein or surrounding tissue

Condition Intervention Phase
Detection of the Correct Position of Intravenous Line
Drug: sodium bicarbonate 4.2%
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Diagnostic
Official Title: Phase III Study to Assess the Utility of a New Innovative Technique Using Intravenous Bicarbonate to Verify the Correct Position of Patients Scheduled for Intravenous Bicarbonate

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • change in exhaled end tidal co2 [ Time Frame: 1-3 minutes ] [ Designated as safety issue: Yes ]
    the injection of bicarbonate in a vein cause a rapid and distinct change in exhaled end-tidal CO2

Estimated Enrollment: 100
Study Start Date: December 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IV bicarbonate 4.2% 20 cc
injecting 20cc 4.2% to a newly administered IV line
Drug: sodium bicarbonate 4.2%
Placebo Comparator: IV normal saline
injecting 20 cc normal saline to a newly administered IV line

Detailed Description:

The method was proved useful in previous phase I, II studies. Now the investigators move on to assess the method in a phase III study in oncological patients.

each patients which will be subjected to intravenous chemotherapy will be eligible ( see also inclusion/exclusion criteria).

Once consent obtained the patient will have an IV line placed. each line placed will be categorized by the clinical team into 3 categories:

  1. IV in place ready to use for chemotherapy ( good blood return)
  2. Doubtful position ( no blood return/ little blood return bu flushes well).
  3. IV not in place. Study design Category 1. IV bicarbonate 4.2% 20 cc and NS 20 cc in a randomized fashion Category 2. same as above Category 3. No injections

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-80 oncological disease requires intravenous chemotherapy

Exclusion Criteria:

  • 1. refusal to participate 2. lung disease acute or chronic sPo2 < 92%, PaCO2 > 50 3. renal failure Creatinine > 2 mg% 4. metabolic alkalosis HCO3 > 30 meq/L 5. medication that affect bicarbonate levels: Bicarbonate, Diamox, Fusid 6. obesity BMI > 38 7. congestive heart failure EF < 40 % or clinical signs of congestive heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01748097

Contact: ilan keidan, MD 97235302754

Oncology Clinic Not yet recruiting
Tel Hashomer, Israel, 52621
Contact: ilan keidan, MD    972526669370   
Sheba Medical Center Oncology Recruiting
Tel Hashomer, Israel, 52621
Contact: ilan keidan, MD    07235302754   
Sponsors and Collaborators
Sheba Medical Center
Netherlands: Ministry of Health, Welfare and Sports
  More Information

No publications provided

Responsible Party: Dr. Ilan Keidan, director pediatric anesthesia, Sheba Medical Center Identifier: NCT01748097     History of Changes
Other Study ID Numbers: IV BIC for IVONCOL
Study First Received: December 10, 2012
Last Updated: December 30, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by Sheba Medical Center:
sodium bicarbonate
end tidal carbon dioxide
chemotherapy processed this record on November 25, 2014